Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone.

Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, ...

During a live event, Samuel M. Rubinstein, MD, discussed the outcomes from the KarMMa-3 trial and real-world patients ...

Renal failure in multiple myeloma typically occurs when the kidneys fail to filter waste products from the blood, leading to ...

It has been dubbed a “Trojan horse” treatment because it works by being taken into a cancer cell, before releasing a high ...

A “Trojan horse” therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world ...

During a live event, Konstantinos Sdrimas, MD, and community oncologists discussed patient concerns over CAR T-cell therapy ...

Diagnosed with incurable cancer, Jonathan Gluck reveals how two decades of uncertainty taught him to find resilience through ...

While older millennials currently have the the highest rates, researchers believe cases may continue to rise among younger generations.

"I won't hold my breath, because most of my patients do relapse at some point, but I was really excited about this curve when ...

A multi-institutional study led by the Icahn School of Medicine at Mount Sinai reports one-third of patients with relapsed or ...